Literature DB >> 8396811

Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody.

J E Rodriguez1, T Moninger, C Grose.   

Abstract

Varicella virus is one of the most reclusive human herpesviruses. The virus is not released from infected cultured cells. Rather, infectivity is transferred by fusion of contiguous cells. To further investigate this process, infected cells were viewed by scanning electron microscopy. Thousands of viral particles were observed in elongated clusters overlying the virus-induced syncytia. When virus-infected cells were covered postinfection with medium supplemented with a monoclonal antibody to glycoprotein gpIII (gH homolog), syncytial formation was completely blocked and no progeny viral particles were observed on the surface of the monolayer. Removal of the antibody was followed by rapid progression of cytopathic effect. Addition of antibody to other viral proteins did not alter the infection. Thus, a monoclonal antibody to a single viral determinant on glycoprotein gpIII (gH) can prevent syncytial formation postinfection and block progression of infectivity. Since the same monoclonal antibody can inhibit entry, this study greatly expands the role of antibody in the modulation of herpesvirus infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396811     DOI: 10.1006/viro.1993.1543

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

1.  Pseudorabies virus glycoprotein L is necessary for virus infectivity but dispensable for virion localization of glycoprotein H.

Authors:  B G Klupp; W Fuchs; E Weiland; T C Mettenleiter
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Role of the varicella-zoster virus gB cytoplasmic domain in gB transport and viral egress.

Authors:  Thomas C Heineman; Susan L Hall
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Interaction of allergy history and antibodies to specific varicella-zoster virus proteins on glioma risk.

Authors:  Seung-Tae Lee; Paige Bracci; Mi Zhou; Terri Rice; John Wiencke; Margaret Wrensch; Joseph Wiemels
Journal:  Int J Cancer       Date:  2013-10-31       Impact factor: 7.396

4.  Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex.

Authors:  M T Huber; T Compton
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Authors:  Mir A Ali; Qingxue Li; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

6.  Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Authors:  Yasushi Akahori; Kazuhiro Suzuki; Tohru Daikoku; Masae Iwai; Yoshihiro Yoshida; Yoshizo Asano; Yoshikazu Kurosawa; Kimiyasu Shiraki
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway.

Authors:  Heidi J Zapata; Masako Nakatsugawa; Jennifer F Moffat
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase.

Authors:  T I Ng; L Keenan; P R Kinchington; C Grose
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 9.  How B cells shape the immune response against Mycobacterium tuberculosis.

Authors:  Paul J Maglione; John Chan
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

10.  Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection.

Authors:  Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.